Phenobarbital Versus Benzodiazepine-Based Pathways for Alcohol Withdrawal Syndrome in Critically Ill Adults: A Systematic Review and Meta-Analysis.
Zeeshan M Rizwan, Diane Brown, Simone Barry et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the effectiveness of phenobarbital-based versus benzodiazepine-based pathways for treating alcohol withdrawal syndrome in critically ill adults. The analysis included 12 treatment-oriented studies. Results indicated that phenobarbital pathways were associated with a shorter ICU length of stay (mean difference of -0.60 days), although no significant differences were found in intubation rates or overall hospital length of stay.
Key findings
- Phenobarbital pathways resulted in a shorter ICU length of stay (MD, -0.60 days).
- No significant difference in intubation rates was observed (OR, 0.62).
- Hospital length of stay showed no significant difference (MD, -1.75 days).
- Front-loaded, protocolized phenobarbital pathways may lead to better outcomes, but evidence is very low certainty.
Why it matters
Understanding the comparative effectiveness of treatment pathways for alcohol withdrawal syndrome in critically ill patients is crucial for optimizing care and resource utilization in intensive care settings.